Abstract Serum calcitriol [1, 25(OH) 2 D] levels are low normal in the presence of hypophosphatemia in X-linked dominant hypophosphatemic rickets (XLH) due to elevated serum fibroblast growth factor 23 (FGF23) levels. We report a peculiar finding of markedly elevated serum 1,25(OH) 2 D levels in a patient with XLH complicated by autosomal dominant polycystic kidney disease (ADPKD) and retinitis pigmentosa (RP). She was diagnosed with XLH, ADPKD and RP at the age of 5, 13 and 15 years, respectively. After the diagnosis of ADPKD, the 1,25(OH) 2 D levels increased up to 282 pg/mL treated with a pharmacological dose of 1aOHD 3 (1aOHD 3 ). At the age of 17 years, under a physiological dose, serum 25-hydroxyvitamin D 3 (25OHD 3 ) and 1,25(OH) 2 D levels were 14.0 ng/mL and 93 pg/mL, respectively. With offtherapy for 3 days, the latter decreased to 9 pg/mL with an increased ratio of 24,25-dihydroxyvitamin D 3 (24,25(OH) 2 D 3 )/25OHD 3 . Serum FGF23 and circulating soluble a-klotho (sKlotho) levels were 552 and 873 pg/ mL, respectively, with the latter being almost half of the normal control. Since the coexistence of elevated serum FGF23 and 1,25(OH) 2 D levels contradicted the conventional FGF23 actions, we speculated on the possible association of decreased sKlotho with the peculiar vitamin D metabolism, although mechanisms in detail remained unknown.
Introduction
X-linked dominant hypophosphatemic rickets (XLH) is characterized by hypophosphatemia, hyperphosphaturia, and vitamin D-resistant rickets [1] . The responsible gene for XLH is the phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) [2] . In XLH, serum calcitriol [1, 25(OH) 2 D] levels were found to be low normal in the presence of hypophosphatemia due to increased serum levels of fibroblast growth factor 23 (FGF23) [3] .
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic renal disease transmitted in an autosomal dominant fashion, characterized by bilateral renal cysts. Gene mutations in PKD1 or PKD2 are responsible for ADPKD [4] . In addition, a truncated polycystin-2, a product of mutated PKD2, was reported to cause retinal degeneration in transgenic rats [5] , which accounts for a rare case of disorder consisting of both ADPKD and RP [6] .
Recently, elevated serum FGF23 levels in the presence of decreased circulating soluble a-klotho (sKlotho) levels were reported in ADPKD patients [7] . Interestingly, hypophosphatemia was observed only in patients with normal sKlotho levels [7] . However, serum 1,25(OH) 2 D levels were within the normal ranges in ADPKD patients [8] .
FGF23 suppresses the synthesis of 1,25(OH) 2 D and promotes its degradation. The action of FGF23 is mediated by the FGF receptors coupled with a full-length transmembrane aklotho [9] . The truncated aklotho is the major form of circulating sKlotho [9] . Moreover, it was reported that sKlotho had its own distinct effect on renal phosphate transport independently of transmembrane aklotho [10] . Therefore, the regulatory mechanism of serum 1,25(OH) 2 D levels by FGF23 and sKlotho is complex and intriguing in ADPKD.
Clinical investigations may present useful data to elucidate the mechanism in a rare case of XLH complicated by ADPKD. In this paper, we describe markedly elevated serum 1,25(OH) 2 D levels in a patient with these rare disorders who had markedly elevated serum FGF23 and moderately decreased serum sKlotho levels simultaneously.
Case
A 5-year-old girl visited Osaka University Hospital complaining of knock-knees and a short stature (-2.4 SD). She was born healthy and had no problems in the perinatal periods. Laboratory investigations revealed hypophosphatemia (2.2 mg/dL), hyperphosphaturia (TmP/GFR: 2.0 mg/dL), and elevated serum ALP values (1399 IU/L) with rickets based on wrist and knee radiographies. The presence of knock-knees, a short stature in addition to hypophosphatemia, hyperphosphaturia, and elevated serum ALP values with rickets suggested that she was suffering from XLH. There was no consanguinity in her family. According to the inquiry from parents, there seemed to be no metabolic bone diseases in her family, although her mother had no brothers in her siblings. Also, blood and urinary bone markers in her parents were within the normal ranges. Under the clinical diagnosis of a sporadic XLH patient, we began to treat her with a pharmacological dose of 1aOHD 3 (0.3 lg/kg/day), and then we gradually reduced the dose in Minoh City Hospital (Fig. 1a) . The therapy normalized serum ALP values at the age of 6 years. Phosphate salts (30 mg/kg/day) were added from the age of 8-14 years. A PHEX gene mutation (c.934-1G[A) was confirmed at 15 years old.She was diagnosed with ADPKD and RP at 13 and 15 years, respectively, on the basis of the family history of her farther suffering from ADPKD and RP. The clinical criteria for the diagnosis of ADPKD were based on the presence of more than 5 extensive cysts in both kidneys on a plain CT imaging test with a slight calcification in the kidney. She did not have the following extra renal manifestations: cysts in the liver, pancreas and arachnoid membrane; intracranial aneurysms; dolichoectasias; aortic root dilatation and aneurysms; mitral valve prolapse; and abdominal wall hernias. A genetic analysis for ADPKD was not done, because both the patient and her guardian did not agree to this investigation. However, we speculated it to be implausible that she was complicated by another rare genetic disease such as nephronophthisis or Bardet-Biedl syndrome. It was because she neither had proteinuria, glycosuria nor abnormal levels of urinary beta 2 microglobulin excretions (223 ng/ml: 38-497). Our speculations seemed to be confirmed by the fact that she neither had neurological problems nor mental retardation.
At the age of 19 years, the increase in cyst volumes was detected. (Fig. 2) . Serum 1,25(OH) 2 D levels began to increase after the clinical diagnosis of ADPKD and reached 282 pg/mL at the age of 13 years (Fig. 1b) . However, serum Ca (Fig. 1d ) and PTH levels ( Fig. 1i) were within the normal range, while urinary excretion of Ca showed only a transient elevation (Fig. 1e) on the maximal dose of 1aOHD 3 (Fig. 1a) . Then, the therapy was stopped for 2 weeks and laboratory data were examined: serum phosphate 1.7 mg/dL, TmP/GFR 1.3 mg/dL, 1,25(OH) 2 D 7 pg/ mL, 25-hydroxyvitamin D 3 (25OHD 3 ) 10.8 ng/mL, intact PTH 28 pg/mL, intact FGF23 316 pg/mL. Renal functions were within the normal ranges: serum Cr 0.45 mg/dL, BUN 15 mg/dL. By contrast, her father had 37 pg/mL of 1,25(OH) 2 D, 11.7 ng/mL of 25OHD 3 , and 36 pg/mL of intact PTH. At the age of 17 years, under a physiological dose of 1aOHD 3 (0.05 lg/kg/day), serum 25OHD and 1,25(OH) 2 D levels were 14.0 ng/mL and 93 pg/mL, respectively. With off-therapy for 3 days, the latter decreased to 9 pg/mL with an increased ratio of 24,25-dihydroxyvitamin D 3 (24,25(OH) 2 D 3 )/25OHD 3 . This value was markedly increased compared with age-matched normal controls [0.202 vs. 0.063 ± 0.03(SD), respectively, n = 49]. Serum 24,25(OH) 2 D 3 and 25OHD 3 levels were, respectively, measured by a high-performance liquid chromatography-tandem mass spectrometry [11] . Also, this increase of 24,25(OH) 2 D 3 /25OHD 3 ratio was confirmed compared to 5 adult XLH patients treated with 1aOHD 3 after adjusting by multiple regression analysis as serum 1,25(OH) 2 D levels for confounders (P = 0.0065). In addition, serum intact FGF23 and circulating sKlotho levels were 552 and 873 pg/mL, respectively, with the latter being almost half of the normal control [12] . They were measured using ELISA kits produced by Kainos Laboratories Inc., (Tokyo, Japan) and Immuno-Biologic Laboratories (Gunma, Japan), respectively. This was an unexpected observation, because the serum 1,25(OH) 2 D levels in patients with XLH are usually at the low normal ranges. Elevated levels of FGF23 contribute to inhibit 25OHD-1a-hydroxylase in the kidney to decrease 1,25(OH) 2 D synthesis [3] . Thus, the markedly increased serum 1,25(OH) 2 D levels in this patient seem to be caused by the blocking of the conventional FGF23 actions. Actually, the 1,25(OH) 2 D level was comparable to or even more than levels reported in patients with XLH after the treatment with neutralizing antibody against FGF23 [3] . However, the rapid decrease of 1,25(OH) 2 D level after the offtherapy with 1aOHD 3 associated with conversion of 24,25(OH) 2 D 3 was not explained by the decreased action of FGF23.
We speculate that the rare complication of ADPKD in this patient with XLH which developed at the age of 13 years may account for the blocking of FGF23 actions, because patients with ADPKD have been reported to show decreased levels of sKlotho [7] . Recently, sKlotho has been shown to exhibit a distinct effect on renal phosphate transport [10] and calcium reabsorption in the renal distal tubules independent of FGF23 actions [13] . In addition, these effects were suggested to be mediated by b-glucuronidase and sialidase associated with sKlotho, respectively [10, 13] . Thus, it is plausible that these mechanisms rather than classical action of FGF23 are linked to the peculiar observation of abnormally increased serum 1,25(OH) 2 D levels even in the presence of elevated serum FGF23 levels in this patient. However, we have no data directly related to these actions of sKlotho in this patient.
One might argue that the extremely high levels of serum 1,25(OH) 2 D levels in this case were caused by the pharmacologically treated dose of 1aOHD 3 . It is possible that (Fig. 1b) in spite of the extremely increased serum FGF23 levels (Fig. 1c) . The reason for the change of the 1,25(OH) 2 D levels remains unexplained. In this patient, TmP/GFR values decreased only slightly (Fig. 1h) in the presence of extremely high serum FGF23 levels after the age of 15 years (Fig. 1c) . This was compatible with the observation that hypophosphatemia is only observed in ADPKD patients with normal sKlotho and elevated FGF23 levels [7] . Thus, a decrease of sKlotho levels possibly acted to ameliorate phosphate leak through its original effect on phosphate transport other than the traditional action of FGF23 through transmembrane aklotho associated with FGF23 receptors.
We did not detect hypercalcemia during the 1aOHD therapy for a long period (Fig. 1d) in spite of the presence of markedly elevated serum 1,25(OH) 2 D levels (Fig. 1b) . One of the possible explanations was the increased urinary excretion of calcium due to decreased sKlotho levels [13] . However, it was not the case because urinary calcium excretion was almost within the normal range after the age of 12 years (Fig. 1e) when the serum 1,25(OH) 2 D levels were extremely elevated (Fig. 1b) . Thus, some other mechanisms of vitamin D resistance might be associated, as previously reported [14] . Further research is necessary to elucidate the mechanism.
In conclusion, a long period of clinical observation in a rare case of XLH complicated by ADPKD and RP for almost 15 years suggested the possible presence of a contribution of sKlotho on serum 1,25(OH) 2 D levels, although the precise mechanism of this regulation needs further investigation.
